Traws Pharma Targets FDA Path for COVID Antiviral

Traws Pharma

NEWTOWN, PA — Traws Pharma Inc. (Nasdaq: TRAW) plans to pursue a regulatory pathway for its experimental COVID-19 treatment in patients unable to take Pfizer’s Paxlovid after a 92-patient Phase 2a trial showed comparable symptom resolution and fewer reported treatment-related adverse events.

The company reported that its once-daily oral antiviral, ratutrelvir, produced a median time to sustained symptom resolution of 13.5 days, compared with 14.5 days for Paxlovid, among patients eligible to receive the approved treatment.

The randomized portion of the study included 62 patients, with 32 receiving ratutrelvir for 10 days and 30 receiving Paxlovid for five days. Both treatments produced similar reductions in viral RNA, and no virologic rebound was observed through Day 28, according to Traws.

Treatment-related adverse events occurred in one ratutrelvir recipient and four Paxlovid recipients. The findings come from a relatively small study and do not establish that ratutrelvir is superior to the approved therapy.

READ:  Mineralys Drug Sustains Blood Pressure Reduction Ahead of FDA Decision

A separate cohort of 30 patients who could not receive Paxlovid, primarily because of contraindicated medications, experienced a median symptom resolution time of 14 days.

Traws reported similar viral clearance rates in that group and no treatment-related adverse events. Participants were generally older and had substantial cardiovascular and pulmonary conditions.

The results support the company’s strategy of targeting patients whose existing medications limit their COVID-19 treatment options.

“These final results support the potential of ratutrelvir as a once-daily, ritonavir-free treatment option, including for patients who cannot take ritonavir-boosted therapy because of their other medications,” said Dr. Robert R. Redfield, Traws’ chief medical officer.

Traws intends to consult the Food and Drug Administration about developing ratutrelvir for adults at high risk of severe COVID-19 who are ineligible for Paxlovid.

The discussions will address a possible adaptive Phase 2b/pivotal clinical program and whether the treatment could qualify for Fast Track designation.

READ:  Exida Launches Cybersecurity Tool Ahead of EU Deadline

Ratutrelvir inhibits the SARS-CoV-2 main protease, an enzyme involved in viral replication. Unlike Paxlovid, the investigational treatment does not require ritonavir, a component associated with significant drug-interaction restrictions.

The company reported laboratory activity against 12 SARS-CoV-2 strains, including activity against certain resistance mutations associated with existing protease inhibitors. Testing against emerging variants, including PJ.2.1, remains underway.

Separately, Traws reported progress in developing tivoxavir marboxil, or TXM, an investigational long-acting antiviral intended to prevent seasonal and pandemic influenza.

A clinical bridging study in healthy volunteers in Australia found that a compressed tablet formulation delivered drug exposure comparable to an earlier powder-in-capsule formulation and was well tolerated.

The results support further evaluation of a potential once-monthly dosing schedule, including a planned human influenza challenge study.

Traws also completed additional toxicology testing following earlier findings involving genetic mutations.

Two independent rat studies using the Pig-a gene mutation assay found no mutagenic effects at doses up to 500 milligrams per kilogram. Effects were observed at 2,000 milligrams per kilogram and inconsistently at 1,000 milligrams per kilogram.

READ:  Orchestra BioMed Raises $80.5M as Pivotal Trial Advances

The company identified 500 milligrams per kilogram as the highest tested dose without an observed mutagenic effect, representing an approximately 125-fold margin over planned clinical exposure based on dose.

Traws expects to resubmit its updated toxicology package to regulators during the fourth quarter of 2026.

TXM has demonstrated preclinical activity against influenza strains, including H5N1 avian influenza, although its effectiveness in preventing human infection has not been established.

Neither ratutrelvir nor TXM has received regulatory approval. Both remain in clinical development as Traws works toward additional studies and regulatory review.

Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.